Trevena rises on initiation of proof-of-concept study for opioid use treatment

Trevena

23/12/2019 13:52

** Shares of drug developer  TRVN.O  rise 6.7% to 79 cents
premarket
    ** TRVN announces initiation of proof-of-concept study for
TRV734, co's experimental treatment for opioid use disorder
 urn:newsml:reuters.com:*:nGNX9vzF51
    ** Says study being funded by National Institute on Drug
Abuse, part of U.S. National Institutes of Health
    ** Up to Friday's close, stock had fallen 72.1% YTD

 (Reporting by Ruhi Soni in Bengaluru)
 ((Ruhi.Soni@thomsonreuters.com;))